Purdue-developed imaging drug allowed surgeons to find additional cancer lesions WEST LAFAYETTE, Ind. — Ovarian cancer patient Carol Giandonato admits to being apprehensive when her oncologist told her he wanted to make her cancer cells turn fluorescent green. "Am I going to glow in the dark? Will I be green?" she asked him. Her surgeon explained that when viewing the cancer site, the cancerous lesions would be illuminated with near-infrared light during surgery. Using this approach, her surgeon was able to find a hidden tumor that would have otherwise gone undetected. Giandonato was one...

The use of ICG and fluorescence imaging is growing exponentially. However, variation continues to exist in how ICG is dosed and administered, and in many other technical aspects of its use.Numerous other issues remain, as well, like indications and contraindications, whether it still should be considered experimental, whether specific patient consent is required, etc. No current consensus technical guidelines exist regarding the indications for and use of ICG A series of surveys are currently underway to assess current practices and, ultimately, see if consensus can be reached regarding...

Vistamerica announced the approval of VistaVerde ICG in Mexico: Available on market in October 2020 Puerto Peñasco, Sonora. Read More

Bile duct injuries during laparoscopic cholecystectomy remain a potentially devastating complications and are responsible for major 1 morbidity and prolonged hospitalization . Visual misperception, anatomical variations in the extrahepatic biliary tree, combined with inflammatory changes and surgeon inexperience in recognizing the 2 anatomy, are among the most common reasons for these injuries . Near-infrared Incisionless Fluorescent Cholangiography (NIFC) has been shown to improve the visualization and identification of the biliary structures compared to traditional white light. Read more...

Appreciating the travel bans and cancellations of many public events around the world we want our customers to know that we will continue to supply ICG for your hospitals.  Our supply chain is very robust and we manage our risk mitigation to ensure we maintain 100% fill rates.  So, you can continue to plan and manage your patient procedures with confidence knowing our drug(s) will be available.   Thank you for your business, Rick MannerPresident - Diagnostic Green